Yolia Health, based in Mexico City, specializes in developing innovative medical equipment aimed at preserving, restoring, and enhancing vision. The company has created The True Vision Treatment (TVT), a non-invasive solution designed to address common vision issues such as presbyopia, myopia, and hyperopia. TVT allows patients to self-administer treatment at home using a combination of customized contact lenses and specially formulated eye drops. After only five days of treatment, patients can typically cease using both the contact lenses and eye drops, as well as their reading glasses, for up to 12 months before requiring re-treatment. Notably, Yolia's approach not only corrects near vision but also improves distance vision, distinguishing it from other alternatives on the market. The company is actively seeking sophisticated investors and industry partners to further its mission.
CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.
Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
Glori Energy is a development stage company focused on enhancing oil recovery from existing well reservoirs without the need for new drilling. The company's mission is to safely and efficiently extract billions of barrels of oil that are otherwise trapped. To achieve this, Glori partners with oil producers to implement the AEROTM (Activated Environment for Recovery of Oil) System, which significantly boosts oil production. This innovative system offers a cost-effective and environmentally friendly solution for recovering previously inaccessible oil, thereby facilitating its entry into the market.
CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.
SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.
SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.
Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer treatment. Founded in 2005 and formerly known as Tragara Pharmaceuticals, the company specializes in proprietary medicines aimed at improving patient outcomes in oncology. One of its key products is an oral multi-kinase inhibitor, designed to effectively inhibit critical cyclin-dependent kinases, thereby enhancing the survival and quality of life for patients with various cancers. Adastra Pharmaceuticals is dedicated to advancing patient care through its responsible approach to oncology.
Molecular Biometrics, Inc., is applying novel metabolomic technologies to develop accurate, non-invasive methodologies for evaluating normal biologic function in health and disease, and for drug discovery and development. The company's proprietary technology is being applied in reproductive health, neurodegenerative disease (Alzheimer's disease and Parkinson's disease), maternal fetal medicine, pulmonary metabolism and edema, and lactate metabolism.
CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.
Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.
Coherex Medical, Inc. develops medical devices for addressing the structural heart disease conditions. It offers patent foramen ovale (PFO) closure system, which is designed to stimulate tissue in-growth to ensure long-term closure of the PFO. The company was founded as Proximare, Inc. in 2003 and changed its name to Coherex Medical, Inc. in 2006. The company is based in Salt Lake City, Utah.
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Claros Diagnostics, Inc. develops innovative products aimed at transforming in-vitro medical diagnostic testing by making it accessible outside of laboratory settings. The company has created a handheld immunoassay system designed for point-of-care blood testing, which includes a portable analyzer and a disposable cassette capable of assessing multiple biomarkers. This system facilitates the testing of various medical conditions, including infectious diseases, cancer, and immune disorders, empowering both physicians and patients with timely diagnostic capabilities.
Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of antibiotics aimed at treating bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which target acute bacterial skin infections and gram-negative pathogens. Melinta's mission is to address the urgent need for effective antibiotics to combat drug-resistant infections, a significant public health challenge. The company is actively advancing its late-stage investigational antibiotic, delafloxacin, currently in Phase 3 development for acute bacterial skin and skin structure infections. Additionally, Melinta is engaged in research aimed at developing new antibiotics to tackle resistant pathogens associated with serious hospital-acquired infections. Melinta Therapeutics maintains license agreements with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., and is supported by investors such as Vatera Healthcare Partners and Warburg Pincus.
LUCA Technologies is developing long-term, biotechnology-driven solutions to rising U.S. dependence on foreign energy sources. Addressing the $150 billion domestic natural gas market, the company is leveraging the ability of naturally occurring microorganisms to convert under-utilized domestic oil, organic-rich shale and coal resources to clean, renewable energy. The company initially expects to provide consulting services to existing energy producers, helping them to evaluate their current oil, organic-rich shale and gas holdings for the presence of natural Geobioreactors or the potential for Geobioreactor stimulation.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Molecular Biometrics, Inc., is applying novel metabolomic technologies to develop accurate, non-invasive methodologies for evaluating normal biologic function in health and disease, and for drug discovery and development. The company's proprietary technology is being applied in reproductive health, neurodegenerative disease (Alzheimer's disease and Parkinson's disease), maternal fetal medicine, pulmonary metabolism and edema, and lactate metabolism.
Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.
ZettaCore is pioneering the field of molecular electronics. The company is focused on developing molecular materials to service the electronics industry. Their unique chemistry leverages the existing manufacturing infrastructure and enables the transition to higher performance at lower cost.
BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.
Laboratory Partners, Inc. provides clinical diagnostic testing services for healthcare providers, including both hospitals and private practices. Laboratory Partners, Inc. is based in Palo Alto, California.
HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgery requirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Courtagen Life Sciences is a biotech company that provides proteomic and genomic products and services to the life sciences industry. The company delivers tools that enable researchers and clinicians to make better decisions regarding drug development and patient care. It was founded in 1999 and headquartered in Woburn, Massachusetts.
Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, that specializes in the discovery and development of engineered monoclonal antibodies and protein therapeutics aimed at treating severe and life-threatening diseases. The company utilizes its proprietary XmAb technology platform to create a range of antibody product candidates targeting conditions such as cancer and autoimmune diseases. Notable candidates include XmAb5871 and XmAb7195, which have completed various phases of clinical trials, and XmAb14045, currently in Phase I for acute myeloid leukemia. Xencor also develops bispecific antibodies, such as AMG424 and AMG509, which are in different stages of clinical and preclinical development for various cancers. The company generates revenue through research and development collaborations and licensing agreements with several prominent pharmaceutical organizations. Founded in 1997, Xencor is focused on addressing unmet medical needs through innovative therapeutic solutions.
LUCA Technologies is developing long-term, biotechnology-driven solutions to rising U.S. dependence on foreign energy sources. Addressing the $150 billion domestic natural gas market, the company is leveraging the ability of naturally occurring microorganisms to convert under-utilized domestic oil, organic-rich shale and coal resources to clean, renewable energy. The company initially expects to provide consulting services to existing energy producers, helping them to evaluate their current oil, organic-rich shale and gas holdings for the presence of natural Geobioreactors or the potential for Geobioreactor stimulation.
Ceres is a non-profit organization focused on promoting sustainability leadership among businesses and investors. Based in Boston, Massachusetts, it mobilizes a diverse network of stakeholders, including companies and public interest groups, to enhance the adoption of sustainable practices that contribute to a healthier economy. Ceres conducts research on various aspects of business sustainability, examining trends and responses within sectors such as insurance, banking, and electric utilities, particularly concerning climate change and emissions. The organization also emphasizes the importance of climate risk disclosure and fuel economy standards in its efforts to advocate for a more sustainable future.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Intechra, LLC, an electronics lifecycle management company, provides information technology asset disposition, value recovery, and computer recycling services to businesses and governments. It offers information technology asset disposition service, such as data security, service plans, and computer remarketing services. The company also provides logistics services, including chain of custody, secured transport, and on-site services. In addition, it offers recycling of ferrous and nonferrous metals, circuit boards, wires and cables, CRT glass and CRT units, batteries, and mercury-containing devices; and plastic casings, storage media, and software disks. Further, the company operates an online store; and sells laptops, personal computers, and computer parts. It serves small and mid-sized businesses, cities, and schools. Intechra, LLC was formerly known as Recycled Computers International, LLC. The company was founded in 1987 and is based in Jackson, Mississippi.
CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.
Coherex Medical, Inc. develops medical devices for addressing the structural heart disease conditions. It offers patent foramen ovale (PFO) closure system, which is designed to stimulate tissue in-growth to ensure long-term closure of the PFO. The company was founded as Proximare, Inc. in 2003 and changed its name to Coherex Medical, Inc. in 2006. The company is based in Salt Lake City, Utah.
Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.
Nfocus Neuromedical
Series B in 2007
Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.
Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer treatment. Founded in 2005 and formerly known as Tragara Pharmaceuticals, the company specializes in proprietary medicines aimed at improving patient outcomes in oncology. One of its key products is an oral multi-kinase inhibitor, designed to effectively inhibit critical cyclin-dependent kinases, thereby enhancing the survival and quality of life for patients with various cancers. Adastra Pharmaceuticals is dedicated to advancing patient care through its responsible approach to oncology.
Claros Diagnostics, Inc. develops innovative products aimed at transforming in-vitro medical diagnostic testing by making it accessible outside of laboratory settings. The company has created a handheld immunoassay system designed for point-of-care blood testing, which includes a portable analyzer and a disposable cassette capable of assessing multiple biomarkers. This system facilitates the testing of various medical conditions, including infectious diseases, cancer, and immune disorders, empowering both physicians and patients with timely diagnostic capabilities.
CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.
HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgery requirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts.
HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgery requirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts.
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Solstice Neurosciences is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. Solstice's first product named Myobloc® (rimabotulinumtoxinB) Injection in the U.S. and NeuroBloc® (Botulinum Toxin Type B) Injectable Solution in select overseas markets, represents the only botulinum toxin type B currently available to physicians and patients worldwide.
Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of antibiotics aimed at treating bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which target acute bacterial skin infections and gram-negative pathogens. Melinta's mission is to address the urgent need for effective antibiotics to combat drug-resistant infections, a significant public health challenge. The company is actively advancing its late-stage investigational antibiotic, delafloxacin, currently in Phase 3 development for acute bacterial skin and skin structure infections. Additionally, Melinta is engaged in research aimed at developing new antibiotics to tackle resistant pathogens associated with serious hospital-acquired infections. Melinta Therapeutics maintains license agreements with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., and is supported by investors such as Vatera Healthcare Partners and Warburg Pincus.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs for central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for its product NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is actively advancing pimavanserin through Phase III clinical trials for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as exploring its use for major depressive disorder. The company operates two subsidiaries in Sweden and Denmark and is committed to discovering novel treatments for conditions such as Alzheimer's and schizophrenia, while also seeking to in-license or acquire complementary products. Acadia holds several patent applications related to its proprietary technology, including innovative methods for drug discovery and development.
Courtagen Life Sciences is a biotech company that provides proteomic and genomic products and services to the life sciences industry. The company delivers tools that enable researchers and clinicians to make better decisions regarding drug development and patient care. It was founded in 1999 and headquartered in Woburn, Massachusetts.
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases. These conditions represent areas of high unmet medical need, often involving orphan and niche indications that currently lack effective therapies. The company focuses on various therapeutic segments, including neuro-ophthalmological, pulmonary, and neuromuscular diseases. Santhera primarily generates its revenue from the European Union, aiming to address significant health challenges faced by patients with these rare disorders.
Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.
FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.
BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.
Solstice Neurosciences is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. Solstice's first product named Myobloc® (rimabotulinumtoxinB) Injection in the U.S. and NeuroBloc® (Botulinum Toxin Type B) Injectable Solution in select overseas markets, represents the only botulinum toxin type B currently available to physicians and patients worldwide.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.
Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting conditions such as osteoarthritis, inflammation, and type II diabetes. Established in 2002 and located in Cambridge, Massachusetts, the company specializes in innovative therapeutic approaches, including Dipeptidyl and Peptidase IV inhibitors. In addition to its core areas, Alantos explores various tissue remodeling pathways to address a range of medical issues, including rheumatoid arthritis, liver fibrosis, cardiovascular conditions, chronic wound healing, and cancer.
Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs for central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for its product NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is actively advancing pimavanserin through Phase III clinical trials for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as exploring its use for major depressive disorder. The company operates two subsidiaries in Sweden and Denmark and is committed to discovering novel treatments for conditions such as Alzheimer's and schizophrenia, while also seeking to in-license or acquire complementary products. Acadia holds several patent applications related to its proprietary technology, including innovative methods for drug discovery and development.
Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.
CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.
FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.
Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.
Courtagen Life Sciences is a biotech company that provides proteomic and genomic products and services to the life sciences industry. The company delivers tools that enable researchers and clinicians to make better decisions regarding drug development and patient care. It was founded in 1999 and headquartered in Woburn, Massachusetts.
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.
IntraPace® has developed a novel implantable system to treat obesity. It is built on the proven technology used in millions of cardiac pacemakers and defibrillators each year. The abiliti® system is designed to be implanted via standard laparoscopic instruments without making any changes to the anatomy of the digestive system or placing any limitations on what a person can eat or drink.
Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. Our product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.
PowderMed
Series A in 2004
PowderMed developed vaccines for the treatment of chronic infectious diseases and cancer. The company used DNA coated gold particles delivered by a needle-free injection device to stimulate a powerful and specific T cell immune response.
Ensemble Therapeutics Corporation is engaged in the discovery and development of small molecule therapies aimed at treating cancer and other serious diseases. The company focuses on creating innovative therapies, particularly in the field of immuno-oncology, targeting mechanisms such as Indoleamine 2, 3-dioxygenase 1 (IDO-1) and components of the ubiquitin proteasome system. Its pipeline includes treatments that inhibit apoptosis-promoting proteins, which can prevent tumor cell death, as well as targeting Cyclophilins that aid in protein folding. Founded in 2002 and based in Cambridge, Massachusetts, Ensemble Therapeutics aims to provide safe and effective treatment options by addressing previously inaccessible drug targets. The company changed its name from Ensemble Discovery Corporation in June 2010.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.
ZettaCore is pioneering the field of molecular electronics. The company is focused on developing molecular materials to service the electronics industry. Their unique chemistry leverages the existing manufacturing infrastructure and enables the transition to higher performance at lower cost.
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
Accelerated Technologies, Inc. (ATI), a New York based partnership model for the creation and acceleration of cardiovascular devices.
Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics targeting cancer and autoimmune disorders. The company specializes in creating innovative treatments that address unmet medical needs in these critical areas. Through its focused approach, Xanthus Pharmaceuticals aims to advance healthcare solutions that improve patient outcomes and enhance the quality of life for those affected by these diseases.
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.
AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.
Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting conditions such as osteoarthritis, inflammation, and type II diabetes. Established in 2002 and located in Cambridge, Massachusetts, the company specializes in innovative therapeutic approaches, including Dipeptidyl and Peptidase IV inhibitors. In addition to its core areas, Alantos explores various tissue remodeling pathways to address a range of medical issues, including rheumatoid arthritis, liver fibrosis, cardiovascular conditions, chronic wound healing, and cancer.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
BrainGate is a path to a better way of life for severely motor-impaired individuals. Through years of advanced research, BrainGate enables these people with the ability to communicate, interact and function through thought. (view video) BrainGate's mission is to further the advancement of this life-changing technology to promote wider adoption to help impaired individuals communicate and interact with society. For instance, the Cyberkenetics BrainGate Neural Interface is currently the subject of a pilot clinical trial being conducted under an Investigational Device Exemption (IDE) from the FDA. The system is designed to restore functionality for a limited, immobile group of severely motor-impaired individuals. It is expected that people using the BrainGate System will employ a personal computer as the gateway to a range of self-directed activities. These activities may extend beyond typical computer functions (e.g., communication) to include the control of objects in the environment such as a telephone, a television and lights.
Cohesive Technologies
Series B in 2003
Cohesive Technologies Inc. designs, manufactures, and markets breakthrough liquid chromatography (LC) solutions for the drug discovery, pharmaceutical, contract research, and clinical diagnostic industries. The company has developed patented technologies and a wide range of chromatographic products designed to significantly improve productivity by accelerating the separation, purification, and analysis of molecules in bioanalysis. With a strong depth of knowledge in column chemistry, applications, engineering, software development, and quality management, Cohesive Technologies leads the industry in the research, development, and production of LC technologies that accelerate the pace of customers' drug discovery and development efforts.
Sirna Therapeutics is a biotechnology company focused on developing therapies based on RNA interference (RNAi), a groundbreaking scientific discovery with the potential to transform disease treatment. By harnessing the capabilities of RNAi, Sirna Therapeutics aims to create innovative solutions that address various illnesses, positioning itself at the forefront of this emerging field. The company's commitment to advancing RNAi-based therapies highlights its role in the evolving landscape of medical treatment, with the goal of improving patient outcomes through targeted interventions.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs for central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for its product NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is actively advancing pimavanserin through Phase III clinical trials for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as exploring its use for major depressive disorder. The company operates two subsidiaries in Sweden and Denmark and is committed to discovering novel treatments for conditions such as Alzheimer's and schizophrenia, while also seeking to in-license or acquire complementary products. Acadia holds several patent applications related to its proprietary technology, including innovative methods for drug discovery and development.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hemophilia and other rare bleeding disorders. The company specializes in subcutaneous (SQ) coagulation factors designed to enhance blood clotting and improve patient outcomes compared to traditional intravenous (IV) therapies. Its product portfolio includes Marzeptacog alfa (activated), an engineered Factor VIIa that has completed Phase II development for hemophilia A or B patients with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has undergone Phase IIb clinical trials for hemophilia B. Additionally, Catalyst is developing CB 2679d-GT, a Factor IX gene therapy for hemophilia B, and CB 2782-PEG, a long-acting anti-C3 protease for dry age-related macular degeneration (AMD). The company has strategic collaborations with Mosaic Biosciences, Inc. for anti-complement factor 3 products and with Biogen International GmbH for the commercialization of pegylated CB 2782 targeting geographic atrophy associated with dry AMD. Established in 2002, Catalyst Biosciences is headquartered in South San Francisco, California.
Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.
SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.
Impella CardioSystems AG, based in Aachen, Germany, develops, manufactures and markets minimally invasive cardiovascular support systems for numerous indications in the fields of cardiology and coronary surgery. The company's technology is protected by more than 30 European and international patents, and currently employees 50 individuals. For the last 2 years Impella has been affiliated with and assisted by Accelerated Technologies, Inc (ATI), a medical device accelerator located in Hackensack, NJ.